OKYO Pharma: Next Generation Therapeutics for Inflammatory Eye Diseases

Facebooktwitterlinkedinmail

OKYO Pharma: Next Generation Therapeutics for Inflammatory Eye Diseases

OKYO Pharma (LSE: OKYO) is a biopharmaceutical company developing next generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. The Company is developing first in class drug candidates designed to prevent disease instead of controlling it. OKYO’s development portfolio focuses on G Protein Coupled Receptor (GPCR) targeted drugs for treatment of inflammatory eye disease, including dry eye, and non-opioid analgesics for management of ocular and chronic pain.

Facebooktwitterlinkedinmail